The Application of Abatacept in the Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA), as a type of chronic autoimmune disease. It is mainly characterized by invasive synovitis, cartilage destruction, leading to irreversible joint deformity and functional disability. Methotrexate and monoclonal antibody TNF inhibitors (TNFi) have become popular choices for the treatment of RA in recent years. However, these two types of drugs are accompanied by serious side effects and poor tolerance. Therefore, the drugs with significant therapeutic effects, stable safety and long-term use value have become a new direction in the treatment of RA. Abatacept (ABA), as a T-cell inhibitor, has shown good results in this regard and has become a valuable research direction in clinical studies. ABA interrupts T cell-mediated immune responses by inhibiting T cell function without consuming T cells. Activated T cells drive the inflammatory cascade. This causes joint inflammation. Such inflammation leads to irreversible structural damage. Patients with RA experience chronic inflammation. This inflammation occurs specifically in the synovial tissue. The synovial tissue lines the joint capsule. ABA therapy offers a suitable treatment option. It alleviates signs and symptoms of moderate to severe RA. This treatment is intended for adult patients. These patients have shown an inadequate response to at least one prior disease-modifying antirheumatic drug (DMARD). Their condition did not improve sufficiently with that prior DMARD therapy. In addition to introducing the basic pharmacology of abatacept, this article, through the analysis of multiple sets of clinical trial data, has derived the alternative therapy and combination treatment mechanism of abatacept in clinical treatment. Moreover, the clinical data of patients who have been using abatacept for a long time were analyzed to verify its excellent therapeutic effect and safety.